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Bone metastases are frequent complications of malignant melanoma leading to reduced quality of life and significant
morbidity. Regulation of immune cells by the gut microbiome influences cancer progression, but the role of the microbiome
in tumor growth in bone is unknown. Using intracardiac or intratibial injections of B16-F10 melanoma cells into mice, we
showed that gut microbiome depletion by broad-spectrum antibiotics accelerated intraosseous tumor growth and osteolysis.
Microbiome depletion blunted melanoma-induced expansion of intestinal NK cells and Th1 cells and their migration from
the gut to tumor-bearing bones. Demonstrating the functional relevance of immune cell trafficking from the gut to the
bone marrow (BM) in bone metastasis, blockade of S1P-mediated intestinal egress of NK and Th1 cells, or inhibition of their
CXCR3/CXCL9-mediated influx into the BM, prevented the expansion of BM NK and Th1 cells and accelerated tumor growth
and osteolysis. Using a mouse model, this study revealed mechanisms of microbiota-mediated gut-bone crosstalk that
are relevant to the immunological restraint of melanoma metastasis and tumor growth in bone. Microbiome modifications
induced by antibiotics might have negative clinical consequences in patients with melanoma.

Introduction

Microorganisms that inhabit the gut lumen are increasingly recognized as being critical to health and disease (1). One tissue now
known to be regulated by the gut microbiome is bone. Studies
in humans and animal models have implicated the gut microbiome as a regulator of bone mineral density (2), postnatal skeletal
development (3), bone tissue material properties (4), bone mineral absorption (5), and the pathogenesis of osteoporosis (6). The
microbiome is also relevant to the skeletal response to bone-regulating hormones including estrogen (7, 8), parathyroid hormone
(9, 10), and glucocorticoids (11). Reports have also implicated gut
microbiome composition in cancer risk (12), while a dysregulation in host cell and gut microbe interactions, a condition known
as dysbiosis, has been linked to cancer progression (13, 14) and
response to cancer therapeutics (15–17). However, little information is available on whether the gut microbiome plays a role in
osteolytic bone lesions, which are deleterious complications of
many malignancies, including malignant melanoma (18), a frequent and aggressive skin cancer (19).
The progression of bone metastasis requires the interaction
between tumor cells and the tumor microenvironment, includ-
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ing immune cells (20). Among the immune cells involved in the
response to melanoma are natural killer (NK) cells (21) and T
helper 1 (Th1) cells (22). NK cells are a component of the innate
immune system, accounting for nearly 10% of all peripheral lymphocytes (23). NK cells develop in the bone marrow (BM), egress
into the bloodstream, and then migrate to secondary lymphoid
structures including Peyer’s patches and other intestinal lymphoid
tissues (24), where the local mucosal tissue microenvironment
drives the acquisition of site-specific features. For example, in the
gut, NK cells sense commensal bacteria and bacterial products via
Toll-like receptors (TLRs) such as TLR9 (25). These interactions
with the gut microbiome induce NK cell activation and cytolytic
activity, which are signaled by the expression of granzyme B (GrB).
The gut microbiome also promotes NK cell expression of inflammatory cytokines, and upregulates the expression of chemokine
receptors that facilitate their migration to distant organs (26).
Many T cell lineages are also abundant in the gut, where their
differentiation, activation, and migration are regulated by the gut
microbiome (27). Intestinal T cells migrate to sites of inflammation driven by chemokine gradients. For example, the gut microbiome induces the migration of TNF+ T cells and Th17 cells from
the gut to the BM in response to an inflammatory state induced by
estrogen deficiency and hyperparathyroidism (8, 9).
Additional immune cells involved in the response to cancer
are cytotoxic T lymphocytes (CTLs; ref. 28), myeloid-derived
suppressor cells (MDSCs; ref. 29), and mononuclear phagocytes
(30). Reports have shown that the microbiome conditions the
anticancer activity of these cells (31, 32). Together, this evidence
1
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suggests the possibility that the gut microbiome may contribute to
the development and the progression of bone metastasis by regulating the migration of immune cells from the gut to the BM of
tumor-bearing bones.
In the present study we analyzed immune cell lineages
involved in the immune response to cancer and known to be
regulated by the microbiome. We showed that melanoma cell
growth in bone triggers expansion of NK cells and Th1 cells in
the tumor-bearing bones in a gut microbiota–dependent manner.
Accordingly, depletion of the gut microbiota by antibiotic treatment increases the progression of bone metastasis by blunting the
migration of intestinal NK cells and Th1 cells to the BM within the
bone tumor bed. Moreover, pharmacological blockade of NK or
Th1 cell egress from the gut or silencing of NK and Th1 cell influx
into the BM of tumor-bearing bones recapitulated the effects of
microbiota depletion, preventing the expansion of these lineages
in the BM and accelerating the growth of bone metastasis.

Results

Gut microbiota depletion by antibiotics increases tumor growth in
bone by decreasing immune cells in the BM. To investigate the extent
to which the gut microbiota influences bone metastasis, intracardiac or intratibial injections of the luciferase-expressing B16-F10
melanoma cell line, a well-established mouse model of orthotopic
and metastatic melanomas (33, 34), were carried out in 12-weekold C57BL/6 mice. To ablate the gut microbiome, mice were treated with broad-spectrum antibiotics (1 mg/mL ampicillin, 0.5 mg/
mL vancomycin, 1 mg/mL neomycin sulfate, 1 mg/mL metronidazole administered in drinking water) for 3 weeks, starting 2 weeks
before the tumor cell injection, as previously described (3, 8, 9).
Analysis of fecal bacteria–specific DNA confirmed >99% ablation
of the gut microbiota following antibiotic treatment, compared
with non-antibiotic-treated controls (Supplemental Figure 1A;
supplemental material available online with this article; https://
doi.org/10.1172/JCI157340DS1). In mice subjected to intracardiac injections of B16-F10 cells, tumor growth was detected mostly
in the skeleton, although at necroscopy lesions were present in the
lungs, skeletal muscle, peritoneum, uterus, and ovaries. Intratibial
injections led to tumor growth only at the injection site. Assessment of bone tumor growth by luminescence revealed that intracardiac injection of B16-F10 cells was followed by tumor engraftment and growth in the distal femur and proximal tibia at day 5,
and further cancer growth at days 10 and 13. At each time point,
bone tumor burden was greater in antibiotic-treated mice than
in non-antibiotic-treated controls (Figure 1, A and B). Analysis
by ex vivo micro–computed tomography (μCT) scanning of tibial
proximal metaphysis harvested at day 13 revealed that injection of
B16-F10 cells was followed by cortical bone perforation (pseudocolored in yellow) and ectopic bone growth (pseudocolored in red;
Figure 1C). Moreover, perforation number, perforation volume,
perforation thickness, and ectopic bone volume (BV) were greater
in antibiotic-treated mice than in non-antibiotic-treated controls,
while the distance between perforations, indicative of the nonaffected cortical bone, was shorter in antibiotic-treated than in
non-antibiotic-treated mice (Figure 1, D and E). At the tibial midshaft, an area devoid of perforations, a decrease in cortical thickness (Ct.Th) and cortical area (Ct.Ar) with no changes in total area
2

(Tt.Ar) was also detected, indicating that B16-F10 cell injection
caused cortical bone loss. The changes in these indices of cortical
structure were greater in antibiotic-treated tumor-bearing mice
than in non-antibiotic-treated tumor-bearing controls (Figure 1F).
In addition, metaphyseal trabecular BV, trabecular bone volume
fraction (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), and trabecular separation (Tb.Sp), which are indices
of trabecular structure, were all affected by cancer cell injection
(Supplemental Figure 2A). Moreover, in mice injected with cancer
cells, antibiotic treatment resulted in greater alterations of BV/TV
and Tb.Th, in comparison with non-antibiotic-treated controls.
To corroborate these studies, we used a further experimental
model, the intratibial injection of B16-F10 cells. Following intratibial B16-F10 cell injection, tumor growth peaked at day 15. At each
time point measured, tumor burden was greater in antibiotic-treated
mice than in non-antibiotic-treated controls (Figure 2, A and B).
μCT analysis of tibiae harvested at day 15 revealed tumor-induced
cortical perforations and ectopic bone growth in the proximal
metaphysis. These lesions were greater in tumor-injected bones of
antibiotic-treated mice compared with the tumor-injected legs of
non-antibiotic-treated mice (Figure 2, C–E). Midshaft Ct.Th and
Ct.Ar were decreased by tumor growth in all groups, but among the
tumor-injected mice, cortical bone loss was more severe in antibiotic-treated mice than in non-antibiotic-treated controls (Figure
2F). These data suggest that in mice subjected to the intratibial
injection of B16-F10 cells, microbiota depletion by antibiotic treatment increased tumor burden and worsened tumor-induced osteolysis and ectopic bone formation. All indices of trabecular volume
and structure in the proximal metaphysis were negatively affected
by cancer cell injection. These alterations were significantly exacerbated by antibiotics (Supplemental Figure 2B).
To confirm that the effects of broad-spectrum antibiotics on
bone tumor burden and osteolysis arose from direct effects of antibiotics on the intestinal bacteria, rather than from off-target effects
of antibiotics, mice were treated with 2 nonabsorbable antibiotics (2 mg/mL neomycin sulfate, 2 mg/mL bacitracin dissolved in
drinking water) for the duration of the experiment, starting 2 weeks
before the tumor cell injection. The effectiveness of nonabsorbable antibiotics was similar to that of broad-spectrum antibiotics,
as they ablated the gut microbiota by >99%, compared with controls (Supplemental Figure 1B). Intracardiac injection of B16-F10
cells was followed by bone tumor growth that peaked at day 13. At
each time point, tumor burden was greater in mice treated with
nonabsorbable antibiotics than in non-antibiotic-treated controls
(Supplemental Figure 3, A and B). μCT analysis of tibiae revealed
that injection of B16-F10 cells led to cortical bone perforation and
ectopic bone growth. The number of perforations, perforation volume, perforation thickness, and ectopic bone volume were greater
in mice treated with nonabsorbable antibiotics than in non-antibiotic-treated controls (Supplemental Figure 3, C–E). The distance
between perforations and midshaft, Ct.Ar, and Ct.Th were lower in
nonabsorbable antibiotic–treated mice than in nontreated controls
(Supplemental Figure 3F). In addition, indices of trabecular structure were all affected by cancer cell injection. Alterations of these
indices were exacerbated by antibiotics (Supplemental Figure 4A).
Nonabsorbable antibiotics were also administered to mice
subjected to intratibial injection of B16-F10 cells. In these exper-
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Figure 1. Antibiotics-induced microbiota depletion accelerates bone tumor growth caused by intracardiac injections of melanoma cells. Intracardiac
injections of luciferase-expressing B16-F10 melanoma cell line were carried out in 12-week-old C57BL/6 mice. Mice not injected with B16-F10 cells (No
tumor) were used as controls. Mice were treated with broad-spectrum antibiotics (1 mg/mL ampicillin, 0.5 mg/mL vancomycin, 1 mg/mL neomycin sulfate,
1 mg/mL metronidazole dissolved in water) for 4 weeks, starting 2 weeks before the tumor cell injection. (A and B) Effects of antibiotics (Abx) on tumor
growth as assessed by luminescence. (C–E) Effects of Abx on bone perforations and ectopic bone growth as assessed by μCT scanning. (C) Representative
images of the tibia. Yellow pseudocolor, perforations; red pseudocolor, ectopic bone growth. (D and E) Indices of perforation and ectopic bone formation.
(F) μCT indices of cortical structure measured in tibial diaphysis. n = 10 mice per group. Data are expressed as mean ± SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.
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Figure 2. Antibiotics-induced microbiota depletion accelerates bone tumor growth caused by intratibial injections of melanoma cells. Intratibial
injections of luciferase-expressing B16-F10 melanoma cell line were carried out in 12-week-old C57BL/6 mice. The noninjected contralateral leg (Cont leg)
was used as a control. Mice were treated with broad-spectrum antibiotics for 4 weeks, starting 2 weeks before the tumor cell injection. (A and B) Effects of
antibiotics on tumor growth as assessed by luminescence. (C–E) Effects of antibiotics on bone perforations and ectopic bone growth as assessed by μCT.
(C) Representative images of the tibia. Yellow pseudocolor, perforations; red pseudocolor, ectopic bone growth. (D and E) Indices of perforation and ectopic
bone formation. (F) μCT indices of cortical structure measured in tibial diaphysis. n = 10 mice per group. Data are expressed as mean ± SEM. All data were
normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. *P < 0.05,
**P < 0.01, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.
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Figure 3. Antibiotics-induced microbiota depletion blocks the expansion of BM NK cells and Th1 cells caused by intracardiac and intratibial injection
of melanoma cells. Intracardiac or intratibial injections of luciferase-expressing B16-F10 melanoma cell line were carried out in 12-week-old C57BL/6
mice. In the intracardiac model, mice not injected with B16-F10 cells (No tumor) were used as controls. In the intratibial model, the noninjected contralateral leg (Cont leg) was used as control. Mice were treated with broad-spectrum antibiotics for 4 weeks, starting 2 weeks before the tumor cell
injection. (A and E) Relative frequency of PP NK (NK1.1+CD3+) cells. (B and F) Relative frequency of PP Th1 (CD3+CD4+IFN-γ+) cells. (C and G) Relative and
absolute frequency of BM NK cells. (D and H) Relative and absolute frequency of BM Th1 cells. (A–D) Intracardiac injections. (E–H) Intratibial injections.
n = 10 mice per group. Data are expressed as mean ± SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests
applying Bonferroni’s correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.

iments, local tumor growth peaked at day 15. At each time point,
bone tumor burden was greater in nonabsorbable antibiotic–treated mice than in untreated controls (Supplemental Figure 5, A and
B). μCT analysis of tibiae harvested at day 15 revealed that cancer
cells caused cortical bone perforation and ectopic bone growth.
Perforation indices and ectopic bone volume were more affected
in nonabsorbable antibiotic–treated mice than in non-antibiotictreated controls (Supplemental Figure 5, C–E). Midshaft Ct.Ar
and Ct.Th were more significantly decreased by cancer growth
in antibiotic-treated mice than in non-antibiotic-treated mice
(Supplemental Figure 5F). Indices of trabecular structure were all
affected by cancer cell injection and further exacerbated in antibiotic-treated mice (Supplemental Figure 4B). Since nonabsorbable
antibiotics and broad-spectrum antibiotics were both effective in
altering the measured indices, it is unlikely that the activity of antibiotics is due to an off-target effect of these agents.
Gut microbiota depletion by antibiotics impacts NK and Th1 cell
frequency in the BM. Little information is available on the effects
of the microbiome on NK cells and Th1 cells. To investigate this,
the frequency of NK cells (CD45+CD3–NK1.1+ cells) and Th1 cells
(CD3+TCRβ+CD4+IFN-γ+ cells) in the Peyer’s patches (PPs) and in

the BM was determined by flow cytometry (Supplemental Figure
6) using samples harvested at sacrifice. Because the measurement of the absolute number of PP cells is technically challenging
owing to variability of the size of the collected PP tissue, NK cells
and Th1 cells in PPs were quantified as percentage of total cells.
In non-antibiotic-treated mice, intracardiac injection of B16-F10
cells caused no changes in PP NK and Th1 cell frequencies (Figure
3, A and B). By contrast, the frequency of both NK cells and Th1
cells increased in response to tumor cell injection in the BM (Figure 3, C and D). Broad-spectrum antibiotics lowered the frequency of PP and BM NK cells and Th1 cells in healthy controls and
in cancer cell–injected mice (Figure 3, A–D). As a result, while intracardiac melanoma cell injection increased the frequency of BM
NK cells and Th1 cells in non-antibiotic-treated controls, it did not
affect the frequency of BM NK cells and decreased the frequency
of BM Th1 cells in antibiotic-treated mice (Figure 3, A–D). These
data demonstrated a role for the gut microbiome in the changes in
immune response to cancer cells in bone.
Studies conducted using the intratibial injection of B16-F10
cells confirmed these findings. In fact, intratibial melanoma cell
injection did not affect the frequency of PP NK cells and Th1 cells
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(Figure 3, E and F) but increased the frequency of NK cells and Th1
cells within the tumor-bearing bones of mice not treated with antibiotics (Figure 3, G and H). Moreover, antibiotic treatment lowered the frequency of PP and BM NK cells and Th1 cells in healthy
controls and in cancer cell–injected mice (Figure 3, E–H).
Analysis of CD8+ T cells, cytolytic CD8+ T cells (GrB+ CD8+
T cells), polymorphonucleated MDSCs, and monocytic MDSCs
— cell populations involved in immune responses to cancer —
revealed that microbiome depletion by antibiotics decreased the
relative frequency of most of these populations in PPs (Supplemental Figure 7). By contrast, antibiotics either did not affect or
increased the absolute frequency of CD8+ T cells, GrB+ CD8+ T
cells, polymorphonucleated MDSCs, and monocytic MDSCs in
the BM (Supplemental Figure 7). The finding of discordant effects
of antibiotics on the analyzed cell lineages in PPs and BM indicated that trafficking of intestinal CD8+ T cells and MDSCs to the BM
does not contribute to the cancer cell–induced expansion of these
lineages in the BM.
Intracardiac injection of B16-F10 cells in mice treated with
nonabsorbable antibiotics did not change the frequency of NK
cells, GrB-expressing (GrB+) activated NK cells, and Th1 cells in
PPs (Supplemental Figure 8A). However, NK cells, GrB+ NK cells,
and Th1 cells in BM increased in response to tumor cell injection
(Supplemental Figure 8B). Nonabsorbable antibiotic treatment
lowered the frequency of PP and BM NK cells, GrB+ NK cells,
and Th1 cells in healthy controls and in cancer cell–injected mice
(Supplemental Figure 8, A and B), confirming the results of the
broad-spectrum antibiotic experiment. Similarly, intratibial injection of B16-F10 cells did not affect the frequency of PP NK cells,
GrB+ NK cells, and Th1 cells (Supplemental Figure 8C) but did
increase the frequency of these lineages in the BM (Supplemental
Figure 8D). Moreover, antibiotic treatment lowered the frequency of PP and BM NK cells, GrB+ NK cells, and Th1 cells in healthy
controls and in cancer cell–injected mice (Supplemental Figure
8, C and D). Together, these findings indicate that the capacity of
antibiotics to regulate NK cells and Th1 cells does not result from
an off-target effect of these agents.
B16-F10 cancer cells promote the migration of intestinal immune
cells to the BM via a microbiota-dependent effect. Since intestinal
immune cells are known to migrate to distant organs, bone tumor
growth may cause the homing of these immune cells to the affected bones. Whether this is mediated by direct effects of the tumor or
indirect responses of the BM cells to the tumor is presently unknown.
To directly investigate the effect of cancer bone growth on NK
cells and Th1 cell trafficking, we utilized C57BL/6 Kaede mice (35)
using methods established in our laboratory (8). This mouse strain
offers a sensitive means of tracking the migration from the gut to
anatomically distant sites of any leukocyte population definable
by surface-displayed or intracellular markers. Kaede mice ubiquitously express the photoconvertible protein Kaede, which permanently changes its fluorescence emission from green (518 nm) to
red (582 nm) upon photoactivation with near-UV light (350–410
nm). Once photoconverted in the intestine, red-fluorescing cells
can be detected and enumerated by flow cytometry in other
organs. The photoconversion of intracellular Kaede has no effect
on cellular function and on the homing capacity of T cells (36).
Hereafter, we will refer to photoconverted cells as KaedeR cells.
6

Supplemental Figure 9, A and B, shows the intestine and fluorescence microscopy images of PP cells of a Kaede mouse subjected
or not subjected to photoactivation of the entire dissected organ ex
vivo by exposure to a 390 nm light for 2 minutes. Intracardiac or
intratibial injections of B16-F10 cells were performed in 12-weekold Kaede mice. Nine days later, when bone lesions were well
established and rapidly growing, all animals were subjected to
surgical laparotomy, and 4 PPs per mouse were photoactivated by
exposure to a 390 nm light for 2 minutes. To ensure that no other
cells were photoconverted, the whole mouse was covered with an
aluminum foil blanket. Mice were sacrificed 24 or 48 hours later,
and the number of KaedeR NK cells, GrB+ NK cells, and Th1 cells
in PPs and BM was measured by flow cytometry.
Intracardiac and intratibial injection of B16-F10 cells was
followed by a decrease in the frequency of PP KaedeR NK cells,
GrB+ NK cells (37), and Th1 cells at 24 and 48 hours with a peak at
48 hours (Figure 4, A and E, and Supplemental Figure 9C). These
findings indicated that the egress of NK cells, GrB+ NK cells, and
Th1 cells from PPs increased during bone cancer growth. Analysis of BM cells from healthy mice revealed that approximately
10%–30% of the BM NK cells, GrB+ NK cells, and Th1 cells were
KaedeR T cells (Figure 4, B–D and F–H, and Supplemental Figure
9D). This was consistent with the fact that, since the cells of 4 PPs
per mouse had been photoconverted, a large fraction of the intestinal immune cells with the potential to migrate to the BM were
Kaede red cells. Injection of B16-F10 cells markedly increased the
relative and absolute frequency of BM NK cells, GrB+ NK cells, and
Th1 cells at 24 and 48 hours with a peak at 45%–60% at 24 hours
(Figure 4, B–D and F–H). This effect was site specific, since intracardiac or intratibial injection of B16-F10 cells into Kaede mice
did not increase the migration of KaedeR NK cells, GrB+ NK cells,
and Th1 cells to the spleen or the liver (Supplemental Figure 10, A
and B), tissues where cancer cells were not detected at necroscopy. Together, these data demonstrate that intraosseous melanoma
tumor growth promotes the migration of intestinal NK cells, GrB+
NK cells, and Th1 cells from intestinal tissues to bone.
To determine whether the migration of immune cells from
the gut to the BM was microbiota dependent, Kaede mice were
subjected to intracardiac or intratibial injection of B16-F10 cells.
Some groups of mice were treated with broad-spectrum antibiotics for 3 weeks, starting 2 weeks before the tumor cell injection.
Nine days after the tumor cell injection, all animals were subjected to laparotomy, and 4 PPs per mouse were photoactivated.
Mice were sacrificed 24 hours later, and the number of KaedeR
NK cells, GrB+ NK cells, and Th1 cells in PPs and BM was measured by flow cytometry. In both the intracardiac (Figure 5, A–D)
and the intratibial experimental model (Figure 5, E–H), antibiotics
prevented the decrease in the frequency of PP KaedeR NK cells,
GrB+ NK cells, and Th1 cells induced by injection of B16-F10 cells
(Figure 5, A and E). Antibiotics also completely prevented the
increase in the frequency of these cells in the BM (Figure 5, B–D
and F–H), demonstrating that the melanoma-induced increase in
the migration of PP NK cells, GrB+ NK cells, and Th1 cells induced
by B16-F10 cells was microbiota dependent.
S1PR1 and S1PR5 induce the egress of Th1 and NK1 cells from the
small intestine. The chemokine receptors S1PR1 and S1PR5 are
expressed by T cells and NK cells, respectively (38, 39). These
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Figure 4. Bone tumor growth increases trafficking of NK cells and Th1 cells
from the gut to the BM within the tumor lesion. Intracardiac (A–D) or intratibial
injections (E–H) of B16-F10 cells were carried out in 12-week-old Kaede mice. In
the intracardiac model, mice not injected with B16-F10 cells (No tumor) were used
as controls. In the intratibial model, the noninjected contralateral leg (Cont leg)
was used as control. Nine days later, mice were subjected to surgical laparotomy
to access the PPs in the distal SI. PP cells were photoconverted by exposure to a
390 nm light for 2 minutes. Mice were sacrificed 24 and 48 hours after photoconversion. (A and E) Relative frequency of PP NK (NK1.1+CD3+) cells, GrB+ NK cells,
and Th1 (CD3+CD4+IFN-γ+) cells. (B and F) Relative and absolute frequency of BM
NK cells. (C and G) Relative and absolute frequency of BM GrB+ NK cells. (D and H)
Relative and absolute frequency of BM Th1 cells. n = 6 mice per group. Data are
expressed as mean ± SEM. All data were normally distributed and were analyzed
by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple
comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with
the indicated group. Nonsignificant comparisons are not shown.
J Clin Invest. 2022;132(12):e157340 https://doi.org/10.1172/JCI157340
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Figure 5. Antibiotics-induced microbiota depletion prevents trafficking of NK
cells and Th1 cells from the gut to the BM induced by tumor growth. Intracardiac
(A–D) or intratibial injections (E–H) of B16-F10 cells were carried out in 12-weekold Kaede mice treated or not treated with broad-spectrum antibiotics. In the
intracardiac model, mice not injected with B16-F10 cells (No tumor) were used
as controls. In the intratibial model, the noninjected contralateral leg (Cont leg)
was used as control. Nine days later, mice were subjected to surgical laparotomy
to access the PPs in the distal SI. PP cells were photoconverted by exposure to
a 390 nm light for 2 minutes. Mice were sacrificed 24 hours after photoconversion. (A and E) Relative frequency of PP NK (NK1.1+CD3+) cells, GrB+ NK cells, and
Th1 (CD3+CD4+IFN-γ+) cells. (B and F) Relative and absolute frequency of BM NK
cells. (C and G) Relative and absolute frequency of BM GrB+ NK cells. (D and H)
Relative and absolute frequency of BM Th1 cells. n = 6 mice per group. Data are
expressed as mean ± SEM. All data were normally distributed and were analyzed
by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple
comparisons. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with
the indicated group. Nonsignificant comparisons are not shown.
8
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receptors promote the egress of intestinal T cells and NK cells
in response to sensing of circulating S1P (38). To investigate the
hypothesis that melanoma growth in bone promotes the egress
of Th1 cells and NK cells from the intestine through an S1PR1/5mediated mechanism, animals were injected with B16-F10
cells and treated for 3 weeks with the S1PR1 functional antagonist FTY720, the S1PR5 functional antagonist BAF312, or both
FTY720 and BAF312. These agents arrest the exit of lymphocytes
or NK cells from PPs and mesenteric lymph nodes (40, 41) without affecting their function (40–43). In both the intracardiac and
intratibial B16-F10 cell injection models, treatment with FTY720
and/or BAF312 had no effects on the frequency of PP NK cells,
GrB+ NK cells, and Th1 cells, in either control or tumor cell–injected mice (Figure 6, A–C, and Supplemental Figure 11, A–C). Moreover, FTY720 did not affect the increase in BM NK cells and GrB+
NK cells induced by cancer growth (Figure 6, D and E, and Supplemental Figure 11, D and E), while it prevented the tumor-induced
increase of Th1 cells in the BM (Figure 6F and Supplemental Figure 11F). These findings showed that blockade of the egress of Th1
cells from the gut blunts the expansion of these cells in BM via an
S1PR1-mediated mechanism. By contrast, treatment with BAF312
prevented the tumor-induced increase of NK cells and GrB+ NK
cells in the BM (Figure 6, D and E, and Supplemental Figure 11, D
and E) but did not affect the frequency of BM Th1 cells (Figure 6F
and Supplemental Figure 11F), demonstrating that S1PR5 signaling mediates the egress of NK cells from the gut and their homing
to the BM. In agreement with this hypothesis, treatment with both
FTY720 and BAF312 prevented the tumor-induced increase of NK
cells, GrB+ NK cells, andTh1 cells in the BM (Figure 6, D–F, and
Supplemental Figure 11, D–F).
In mice subjected to intracardiac injection of B16-F10 cells,
treatment with FTY720 or BAF312 alone or in combination similarly increased tumor growth at days 10 and 13 (Figure 7A), worsened tumor-induced metaphyseal perforations and ectopic bone
growth (Figure 7B), worsened midshaft cortical bone loss without
affecting bone area (Figure 7C), and aggravated metaphyseal trabecular bone loss (Supplemental Figure 12A). Comparable effects
of treatment with FTY720 and/or BAF312 were found in mice subjected to intratibial injection of B16-F10 cells. In fact, in this experimental model, treatment with FTY720 or BAF312 or with both
increased tumor growth at 5, 10, and 15 days (Supplemental Figure 13A), worsened cortical perforation indices and ectopic bone
growth (Supplemental Figure 13B), aggravated cortical bone loss
without affecting bone area (Supplemental Figure 13C), and worsened trabecular bone loss (Supplemental Figure 12B). No significant differences were detected between these effects of FTY720,
BAF312, or combined FTY720 and BAF312 treatment.
CXCR3 and CXCL9 induce the influx of Th1 cells and NK1 cells
into the BM. While the egress of Th1 and NK cells from intestinal
lymphoid tissues and their entrance into the bloodstream are driven by the S1PR1/5 receptors and their ligand S1P, the exit from
the systemic circulation of Th1 and NK cells and their infiltration
of cancers are driven by CXCR3, a receptor expressed by T cells
(44, 45) and NK cells (46), and its ligand CXCL9, which is induced
or upregulated by IFN-γ (47, 48). To determine the relevance of
CXCR3 to melanoma-dependent NK and Th1 cell migration to
the BM, intracardiac or intratibial injections of B16-F10 cells were

performed in 12-week-old Cxcr3 –/– mice and WT littermate controls. In both the intracardiac and the intratibial injection model,
BM levels of Cxcl9 transcripts increased in response to B16-F10
cell growth in both WT and Cxcr3–/– mice (Figure 8, A and F). By
contrast, the frequency of BM NK cells, GrB+ NK cells, and Th1
cells was increased by bone tumor growth in WT but not in Cxcr3–/–
mice (Figure 8, B–D and G–I). As a result, the frequency of NK and
Th1 T cells in the BM of B16-F10 cell–injected mice was lower in
Cxcr3–/– mice than in WT mice, underscoring the critical role of
CXCR3 in NK and Th1 T cell homing to the BM. As expected, the
frequency of these cells in PPs was similar in WT and Cxcr3–/– mice
(Figure 8, E and J). Attesting to the functional relevance of these
effects, measurement of tumor growth by luminescence revealed
that Cxcr3 –/– mice had increased tumor growth as compared with
WT mice (Figure 9, A and B, and Figure 10, A and B). In addition,
Cxcr3–/– mice had more severe cortical perforation indices (Figure
9, C and D, and Figure 10, C and D), ectopic bone growth (Figure 9E and Figure 10E), cortical bone loss (Figure 9F and Figure
10F), and trabecular bone loss (Supplemental Figure 14, A and
B). Together, these data provided evidence that CXCR3 functions
in inducing the influx of Th1 cells and NK1 cells into the BM and
impacts bone tumor growth.
To investigate the role of the CXCR3 ligand CXCL9, intracardiac or intratibial injections of B16-F10 cells were carried out in
12-week-old WT mice. Mice were treated with anti-CXCL9 antibody or isotype-matched irrelevant antibody. In both the intracardiac and the intratibial injection model, the frequency of BM NK
cells, GrB+ NK cells, and Th1 cells was increased by bone tumor
growth in control mice but not in those treated with anti-CXCL9
antibody (Figure 11, A–C and E–G). By contrast, the frequency
of NK cells, GrB+ NK cells, and Th1 cells in PPs was similar in all
groups (Figure 11, D and H). Attesting to the functional relevance of
CXCL9, measurement of tumor growth by luminescence revealed
that mice treated with anti-CXCL9 antibody had increased tumor
growth as compared with those treated with irrelevant antibody
(Figure 12, A and B, and Figure 13, A and B). In addition, CXCL9
neutralization led to more severe cortical perforations (Figure 12,
C and D, and Figure 13, C and D), ectopic bone growth (Figure 12E
and Figure 13E), cortical bone loss (Figure 12F and Figure 13F),
and trabecular bone loss (Supplemental Figure 15, A and B).

Discussion

We report that the gut microbiome restrains the progression of
melanoma bone lesions in mice by promoting the expansion of
intestinal NK cells and Th1 cells and enhancing their migration to
the BM of tumor-bearing bones. To directly investigate the effect
of tumor growth in bone on immune cell trafficking, we made
use of Kaede mice (35). This strain has been successfully used
to track the migration of intestinal immune cells to the BM (8),
kidney (49), mesenteric lymph nodes (50), and brain (51). These
experiments revealed that expansion of melanoma cells in bone
increases the tropism of NK and Th1 cells for the BM in a microbiome-dependent fashion. The homing of NK and Th1 cells to the
BM was specifically directed to the BM within the cancer lesions,
as these cells were not attracted to cancer-free spleen or liver. We
did not find evidence that bone cells or bone-produced factors
are required for intestinal NK and Th1 cells to home to the BM of
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Figure 6. Blockade of Th1 and NK cell egress from the gut prevents the expansion of BM Th1 and NK cells induced by intracardiac injections of melanoma cells. Intracardiac injections of luciferase-expressing B16-F10 melanoma cell line were carried out in 12-week-old C57BL/6 mice. Mice not injected with
B16-F10 cells (No tumor [NT]) were used as controls. Mice were also treated with the S1PR1 functional antagonist FTY720 and/or the S1PR5 functional
antagonist BAF312, starting 1 week before the tumor cell injection. (A) Relative frequency of PP NK (NK1.1+CD3+) cells. (B) Relative frequency of PP GrB+
NK cells. (C) Relative frequency of PP Th1 (CD3+CD4+IFN-γ+) cells. (D) Relative and absolute frequency of BM NK cells. (E) Relative and absolute frequency
of BM GrB+ NK cells. (F) Relative and absolute frequency of BM Th1 cells. n = 5 mice per group. Data are expressed as mean ± SEM. All data were normally
distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown. T, tumor.

tumor-bearing bones, but a possible contribution of bone-specific factors remains to be conclusively determined. These findings
provide novel mechanistic insights into the role of the microbiome
in the development of bone lesions in melanoma, an aggressive
cancer that frequently affects the skeleton.
The egress of NK and Th1 cells from the gut and their entrance
into the bloodstream are driven by the S1P receptor S1PR5 expressed
by NK cells (39, 46), the S1PR1 receptor expressed by Th1 cells (40,
10

41), and the S1PR1/5 circulating ligand S1P (39). In this study the
relevance of intestinal NK cells in regulating the abundance of NK
cells in the BM was demonstrated using BAF312, an S1PR5 modulator that arrests NK cell exit from the BM and intestinal lymphoid
tissues (42, 43). We found that BAF312 did not affect the number of
intestinal NK cells. By contrast, even though BAF312 blunted NK
cells’ exit from the BM, the frequency of NK cells in the BM within cancer lesions was markedly decreased by BAF312 in control
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Figure 7. Blockade of Th1 and NK cell egress from the gut accelerates bone tumor growth induced by intracardiac injections of melanoma cells. Intra
cardiac injections of luciferase-expressing B16-F10 melanoma cell line were carried out in 12-week-old C57BL/6 mice. Mice not injected with B16-F10 cells
(NT) were used as controls. Mice were also treated with the S1PR1 functional antagonist FTY720 and/or the S1PR5 functional antagonist BAF312, starting
1 week before the tumor cell injection. (A) Tumor growth as assessed by luminescence. (B) Bone perforations and ectopic bone growth as assessed by μCT.
(C) μCT indices of cortical structure measured in tibial diaphysis. n = 5 mice per group. Data are expressed as mean ± SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. *P < 0.05, **P < 0.01, ***P < 0.001,
****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.
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Figure 8. Global deletion of CXCR3 prevents the expansion of BM NK and Th1 cells induced by intracardiac and intratibial injection of melanoma cells.
Intracardiac (A–E) and intratibial injections (F–J) of B16-F10 melanoma cells were carried out in 12-week-old C57BL/6 WT and Cxcr3–/– mice. In the intra
cardiac model, mice not injected with B16-F10 cells (No tumor) were used as controls. In the intratibial model, the noninjected contralateral leg (Cont leg)
was used as control. (A and F) BM levels of CXCL9 transcripts. (B and G) Relative and absolute frequency of BM NK cells. (C and H) Relative and absolute
frequency of BM GrB+ NK cells. (D and I) Relative and absolute frequency of BM Th1 cells. (E and J) Relative frequency of PP NK cells, GrB+ NK cells, and Th1
cells. n = 7 mice per group. Data are expressed as mean ± SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests
applying Bonferroni’s correction for multiple comparisons. **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant
comparisons are not shown.

and B16-F10 cell–injected mice. Moreover, BAF312 prevented the
tumor-induced increase in BM NK cells, indicating that an influx of
intestinal NK cells into the BM contributes to the tumor-induced
increase in the frequency of BM NK cells.
The role of intestinal Th1 cells in regulating the size of the pool
of BM Th1 cells was revealed by FTY720, an S1PR1 modulator that
arrests the exit of all lymphocytes from the intestine to the systemic circulation (40, 41). This agent lowered the frequency of BM Th1
cells without affecting the frequency of intestinal Th1 cells. Moreover, FTY720 prevented the tumor-induced increase in BM Th1
cells, demonstrating the relevance of intestinal Th1 cells in regulating the frequency of BM Th1 cells. Since FTY270 and BAF312
block the intestinal egress of all lymphocytes (42, 43), it could
12

be argued that increased cancer growth induced by these agents
might have resulted, in part, from the impaired migration of lymphocytes capable of restraining cancer growth other than NK and
Th1 cells. This hypothesis is unlikely because the acceleration of
bone cancer growth induced by FTY270 and/or BAF312 was comparable to the effects of antibiotics, which blocked the migration
of NK cells and Th1 cells only. We found the influx of NK and
Th1 cells to the BM within cancer lesions to be dependent on the
chemokine receptor CXCR3, which is expressed on NK cells (46)
and T cells (44, 45), and on its ligand CXCL9, which is induced
by IFN-γ (47, 48, 52). Accordingly, the BM cell expression of
CXCL9 was upregulated by B16-F10 cell expansion, while silencing of either the CXCR3 receptor or its ligand CXCL9 blunted the
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Figure 9. Silencing of CXCR3 accelerates bone tumor growth induced by intracardiac injection of melanoma cells. Mice not injected with B16-F10 cells
(No tumor) were used as controls. (A and B) Tumor growth at day 13 as assessed by luminescence. (C–E) Bone perforations and ectopic bone growth as
assessed by μCT. (C) Representative images of the tibia. Red pseudocolor, perforations; yellow pseudocolor, ectopic bone growth. (D and E) Indices of perforation and ectopic bone formation. (F) μCT indices of cortical structure measured in tibial diaphysis. n = 7 mice per group. Data are expressed as mean ±
SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons.
***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.
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Figure 10. Silencing of CXCR3 accelerates bone tumor growth induced by intratibial injection of melanoma cells. The noninjected contralateral leg (Cont
leg) was used as control. (A and B) Tumor growth at day 15 as assessed by luminescence. (C–E) Bone perforations and ectopic bone growth as assessed by
μCT. (C) Representative images of the tibia. Red pseudocolor, perforations; yellow pseudocolor, ectopic bone growth. (D and E) Indices of perforation and
ectopic bone formation. (F) μCT indices of cortical structure measured in tibial diaphysis. n = 7 mice per group. Data are expressed as mean ± SEM. All data
were normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. **P < 0.01,
***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.
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increase in the frequency of BM NK cells and Th1 cells induced by
B16-F10 cell expansion.
Attesting to the relevance of intestinal NK cells and Th1 cells, the
S1P-S1PR1/5 axes, and the CXCR3-CXCL9 chemokine gradient in
restraining bone tumor growth, blockade of NK and Th1 cell egress
from the intestine or blockade of their influx into the BM resulted in
accelerated cancer growth in bone, an effect mirroring the consequences of microbiome ablation by antibiotics. Simultaneous blockade of NK cells or Th1 cell trafficking potentiated cancer growth as
effectively as migration inhibition of one cell lineage only, a finding
consistent with the existence of reciprocal control of the anticancer activity of these 2 lineages (53). Since FTY720 is currently FDA
approved for the treatment of multiple sclerosis (MS), the potential
negative effect of FTY720 in cancer burden may need to be considered if this drug is used in patients affected by melanoma and MS.
NK cells play a key role in the immune response to melanoma (53) and other cancers (21). Upon forming immune synapses
with target cells, NK cells induce cell lysis by releasing cytolytic
granules, including perforin and granzymes (54). In addition to
their direct anticancer activity, NK cells promote Th1 polarization
through multiple mechanisms (53, 55), including IFN-γ production
(56). Th1 cells are primarily responsible for activating tumor antigen–specific cytotoxic T lymphocytes (CTLs) (22). This activation
is mediated by direct cell contact (57), through cytokines (58), or
via the involvement of intermediary cell lineages. In addition, Th1
cells kill tumor cells via release of cytokines that activate death
receptors on the tumor cell surface. A common effector molecule
of NK cells and Th1 cells is IFN-γ. This explains, in part, the overlapping anticancer activities of these 2 lineages. IFN-γ enhances
tumor immunogenicity through the upregulation of MHC class I
expression on tumor cells, thereby making tumor cells sensitive
to CTL-mediated elimination (59). IFN-γ also has antiproliferative, antiangiogenic, and proapoptotic effects against tumor cells
(60–62). IFN-γ is also a critical player in the migration of NK cells
to tumor sites. In fact, IFN-γ induces the expression of the CXCR3
ligand CXCL9 (47), driving the influx of NK cells to the tumor bed.
Antibiotics-induced dysbiosis was previously reported by other investigators to accelerate cancer growth (63–65). Jenkins et al.
reported that injection of B16-F10 melanoma cells resulted in more
rapid local cancer growth in antibiotic-treated mice. Antibiotics
were found to decrease the expression of TNF-α, which resulted in
a decrease in the number of effector T cells (63). In another study,
preexisting dysbiosis caused primary mammary tumors to expand
more rapidly in the breast. Dysbiosis also increased tumor cell
dissemination to the lungs by enhancing inflammation and fibrosis in the mammary gland (64). Recently, McKee et al. reported
that antibiotics resulted in accelerated breast tumor growth via an
increase in the number of mast cells in tumor stroma (65). However, the current study is, to our knowledge, the first to provide evidence for a role of the gut microbiome in the progression of bone
metastasis and provide information about trafficking of immune
cells from the gut to BM within bone lesions.
The role of the microbiota in regulating the contributions
of other cell lineages and cytokines implicated in the immune
response to melanoma remains to be determined, as our investigation was mostly focused on NK and Th1 cells, lineages known to
be directly regulated by the gut microbiota, for which biochemical

reagents are available to follow their migration from the gut to the
BM. Microbial metabolites are also known to regulate the immune
response to cancer. Butyrate was one of the first bacterial products
implicated in cancer progression and response to immune therapy
(66). Novel metabolites and mechanisms of action have been recently described. For example, it has been reported that microbiotaderived stimulators of interferon gene agonists induce production of IFN-1, a factor promoting NK cell–dendritic cell crosstalk,
by intratumor monocytes, thus improving the efficacy of immune
checkpoint blockade in melanoma patients (32). Additional studies will be required to elucidate the multiple mechanisms by which
bacteria and their products affect cancer progression and response
to therapy, either directly or via regulatory activities on intestinal
and tumor-microenvironment immune cells.
In summary, this study reveals mechanisms for microbiotamediated gut-bone crosstalk in mouse models of metastatic melanoma relevant to the immunological restraint of bone cancer growth.
The observation that microbiome depletion accelerates metastatic
bone growth indicates that antibiotics and other causes of dysbiosis
may have unforeseen adverse consequences in melanoma patients.

Methods

Mice. C57BL/6NTac mice were purchased from Taconic Biosciences.
Cxcr3–/– mice (B6.129P2-Cxcr3<tm1Dgen>/J) were purchased from
The Jackson Laboratory. C57BL/6 Kaede mice [B6.Cg-c/c Tg(CAGtdKaede)15Utr] were purchased from RIKEN BioResource Research
Center. All mice entering Emory University were shipped to the same
room in the same vivarium. All mice were housed under specific
pathogen–free conditions and were fed γ-irradiated 5V5R mouse chow
(Purina Mills) and autoclaved water ad libitum. The animal facility
was kept at 23°C (± 1°C) with 50% relative humidity and a 12-hour
light/12-hour dark cycle. All mice were acclimatized within our facility
for at least 3 days before experimentation.
Intracardiac and intratibial B16-F10 cell injection. Luciferaseexpressing B16-F10 melanoma cells (1 × 105) in 100 μL of PBS were
injected into the left cardiac ventricle or the tibia of 12-week-old
female mice as previously described (67–68). The mice were monitored daily for 13–15 days and then sacrificed. For intracardiac injection experiments, control mice without tumors were generated by
injection of PBS only. Control samples for intratibial injection experiments were generated by injection of PBS in the contralateral tibia.
PPs from intracardiac-injection no-tumor groups were used as control
PPs for the intratibial injection experiments.
Depletion of gut commensal microflora. Cocktails of broad-spectrum antibiotics (1 mg/mL ampicillin, 0.5 mg/mL vancomycin, 1 mg/
mL neomycin sulfate, and 1 mg/mL metronidazole; ref. 70) or of nonabsorbable antibiotics (2 mg/mL bacitracin and 2 mg/mL neomycin
sulfate) were included in the drinking water starting at 2 weeks before
initiation of cancer cell injection and continued until sacrifice. Fecal
microbiome depletion was verified by fecal DNA extraction using
QIAamp DNA Stool Mini Kit (QIAGEN) and subsequent quantitative
PCR using an established protocol that used primers specific for the
detection of the 16S rRNA gene present in all bacteria (5′-GTGCCAGCMGCCGCGGTAA-3′, forward; 5′-GGACTACHVGGGTWTCTAAT-3′, reverse), as previously described (9, 10).
FTY720, BAF312, and anti-CXCL9 antibody treatment. The S1PR1
functional antagonist FTY720 (49) was added to the drinking water at
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Figure 11. Antibody neutralization of CXCL9 prevents the expansion of BM NK and Th1 cells induced by intracardiac and intratibial injection of melanoma cells. Intracardiac (A–D) and intratibial injections (E–H) of B16-F10 melanoma cells were carried out in 12-week-old mice. In the intracardiac model,
mice not injected with B16-F10 cells (No tumor) were used as controls. In the intratibial model, the noninjected contralateral leg (Cont leg) was used as
control. Mice were treated with anti-CXCL9 antibody or isotype-matched irrelevant antibody. (A and E) Relative and absolute frequency of BM NK cells.
(B and F) Relative and absolute frequency of BM GrB+ NK cells. (C and G) Relative and absolute frequency of BM Th1 cells. (D and H) Relative frequency of
PP NK cells, GrB+ NK cells, and Th1 cells. n = 5 mice per group. Data are expressed as mean ± SEM. All data were normally distributed and were analyzed by
2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the
indicated group. Nonsignificant comparisons are not shown.
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Figure 12. Antibody neutralization of CXCL9 accelerates bone tumor growth induced by intracardiac injection of melanoma cells. Mice not injected with
B16-F10 cells (No tumor) were used as controls. (A and B) Tumor growth at day 13 as assessed by luminescence. (C–E) Bone perforations and ectopic bone
growth as assessed by μCT. (C) Representative images of the tibia. Red pseudocolor, perforations; yellow pseudocolor, ectopic bone growth. (D and E) Indices of perforation and ectopic bone formation. (F) μCT indices of cortical structure measured in tibial diaphysis. n = 5 mice per group. Data are expressed
as mean ± SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple
comparisons. **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.

5 μg/mL as previously described (8, 9). The S1PR5 functional antagonist BAF312 was delivered by oral gavage (3 mg/kg) as previously
described (71). FTY720 and BAF312 treatments were initiated 1 week
before B16-F10 cell injection and continued until sacrifice. Drinking
water containing FTY720 was changed weekly. Anti–mouse CXCL9
antibody (catalog BE0309, Bio X Cell) or isotype-matched irrelevant

antibody (catalog BE0091, Bio X Cell) was injected i.p. every other
day at 100 μg per mouse, starting 3 days before tumor cell injection
and continued until sacrifice, as previously described (72, 73).
In vivo imaging system–based analysis of tumor growth. Mice were
injected s.c. with 150 mg/kg d-luciferin potassium salt (P/N 122799,
PerkinElmer), anesthetized using isoflurane, and imaged 15 minutes
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Figure 13. Antibody neutralization of CXCL9 accelerates bone tumor growth induced by intratibial injection of melanoma cells. The noninjected contralateral leg (Cont leg) was used as control. (A and B) Tumor growth at day 15 as assessed by luminescence. (C–E) Bone perforations and ectopic bone growth
as assessed by μCT. (C) Representative images of the tibia. Red pseudocolor, perforations; yellow pseudocolor, ectopic bone growth. (D and E) Indices of
perforation and ectopic bone formation. (F) μCT indices of cortical structure measured in tibial diaphysis. n = 5 mice per group. Data are expressed as mean
± SEM. All data were normally distributed and were analyzed by 2-way ANOVA and post hoc tests applying Bonferroni’s correction for multiple comparisons. **P < 0.01, ***P < 0.001, ****P < 0.0001 compared with the indicated group. Nonsignificant comparisons are not shown.

after injection as previously described (68, 74). Imaging was performed
on days 5, 10, and 13 for the intracardiac injection model and on days 5,
10, and 15 for the intratibial injection model. For analysis, total photon
flux (photons per second) was measured from a fixed region of interest
(ROI) in the tumor area using Living Image 4.50 software.
18

μCT-based analysis of tumor-induced cortical perforations and
ectopic bone formation at the femoral and tibial metaphysis. Excised
hind limbs were fixed in 10% neutral-buffered formalin, then
imaged in a μCT40 (Scanco Medical AG). Images were acquired in
the axial plane at 70 peak kilovoltage, 114 μA, 500 projections per
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rotation, and an integration time of 300 milliseconds, then reconstructed using the 1200 mg HA/cm3 beam hardening correction to
generate axial images with 12.0 μm isotropic voxels. Extraperiosteal
orthotopic new bone as well as cortical perforations and connected
surface erosions in the proximal tibial and distal femoral metaphysis was analyzed using a semiautomated algorithm. Briefly, analysis
began with drawing of a “loose” volume of interest (VOI) outside the
metaphyseal cortex leaving at least 100 μm between the contour and
the bone surface, whether cortical or heterotopic, on the axial images at 360 μm to 2400 μm from the proximal tibial or distal femoral
growth plate. The method of Buie et al. (75) was modified to create
masks approximating the smooth periosteal and endosteal surfaces
that span small cortical perforations and erosions, rather than dipping into the surface imperfections. A 3D reconstruction of medullary marrow space and cortical imperfections that extend to the periosteal surface was then created by application of a lower threshold of
0 and an upper threshold of 450 mg HA/cm3, sigma 0.8, and support
2 to the volume inside the periosteal contour. Extraperiosteal space
and cortical perforations that extended to the endosteal surface were
segmented in a similar manner by combination of the hand-drawn
“loose” outer contour with the automated endosteal contour and
application of the same inverse threshold. The intramedullary and
extraperiosteal volumes were concatenated, and the cortical perforations and surface erosions connected to the perforations were
identified as the overlapping volumes present in both objects. The
endocortical and periosteal contours were combined to create a cortical mask of the smoothed bone surfaces inclusive of perforations
and erosions, which served to define total cortical volume for calculation of volumetric and architectural parameters of the perforations.
Standard procedures that are commonly applied to the analysis of
trabecular bone (76–78) were then applied to the perforation images
to calculate cortical volume, perforation volume, perforation number, and perforation thickness.
Ectopic new bone extending from the periosteal surface was segmented by combination of the periosteal and hand-drawn “loose”
contours to create the extraperiosteal VOI, then application of a
threshold of 180 mg HA/cm3 without the Gaussian noise filter. The
volumetric and architectural parameters of ectopic bone were calculated using standard procedures and nomenclature (76–78).
μCT-based analysis of metaphyseal trabecular and midshaft cortical bone volume and architecture. Trabecular and cortical volume
and architecture in the proximal tibial metaphysis, distal femoral
metaphysis, and femoral midshaft were analyzed by μCT as previously reported (79–81) and using the same acquisition settings as
above. The VOI for trabecular analysis was the entire medullary volume lying 0.24 mm to 0.84 mm from the central tip of the growth
plate, and trabecular bone was segmented from soft tissue using a
threshold of 425 mg HA/cm3. Midshaft cortical bone was analyzed
in 50 axial μCT slices comprising the middle 0.60 mm of the femur.
The periosteal and endosteal masks were created as previously
described (75), and cortical bone was segmented using a threshold
of 700 mg HA/cm3, sigma 0.2, and support 1. Cortical and trabecular volumetric and architectural parameters were calculated using
standard methods (76–78).
PP and BM single-cell suspension. For PP cell isolation, the small
intestine (SI) was removed and flushed of fecal content. PPs were
excised and collected in 1 mL cooled RPMI 1640. PPs were dissociated

using the plunger of a 2.5 mL syringe and gently forced through a 70
μm cell strainer placed over a 50 mL tube. A single-cell suspension was
used for flow cytometric analysis. For BM cell isolation, tumor-bearing
femur and tibia were flushed with PBS, and BM cells were collected.
RBC lysis was performed twice to eliminate all the RBCs from BM.
Single-cell suspension of BM cells was used for analysis by flow cytometry, as previously described (9, 10).
Kaede mouse cell photoconversion. Kaede mice express a photoconvertible fluorescence protein that changes from green (518 nm) to
red (582 nm) upon exposure to near-UV (350–410 nm) light. Twelveweek-old segmented filamentous bacteria–positive (SFB+) Kaede mice
were subjected to intracardiac or intratibial B16-F10 tumor cell injection. Nine days later, animals underwent laparotomy, during which the
cecum and distal SI were eviscerated and the 4 PPs most proximal to
the cecum were identified and illuminated with 390 nm wavelength
light for 2 minutes each. Aluminum foil was used to protect tissue other than target PPs from light during exposure. Mice were sacrificed 24
or 48 hours after photoconversion, and PP cells were collected. A single-cell suspension was prepared for analysis by flow cytometry. BM
cells were also collected at sacrifice and a single-cell suspension prepared. BM KaedeR NK and Th1 cells were enumerated by flow cytometry by analysis of whole BM cells.
Flow cytometry. Flow cytometry was performed on a FACS Cytek
Aurora (Cytek Biosciences), and data were analyzed using FlowJo software (Tree Star Inc.). Antibodies and reagents used for surface and
intracellular staining are listed in Supplemental Table 1. The live cells
were discriminated by LIVE/DEAD Fixable Yellow Dead Cell Stain
Kit (Thermo Fisher Scientific). For intracellular staining, cells were
incubated with cell activation cocktail (BioLegend) containing PMA,
ionomycin, and monensin at 37°C for 12 hours. Antibodies were added
after cell fixation and permeabilization.
Real-time reverse transcriptase PCR and primers. Total RNA was
isolated using TRIzol reagent (Thermo Fisher Scientific) according to the manufacturer’s protocol. For all RNA samples, cDNA
was synthesized from mRNA using the SuperScript III First Strand
kit (Invitrogen). The expression levels of CXCL9 were measured in
tumor-bearing BM cells by real-time PCR. Changes in relative gene
expression between groups were calculated by the 2–ΔΔCt method with
normalization by 18S rRNA. Primer sequences used for the experiment were as follows: CXCL9, 5′-AACGTTGTCCACCTCCCTTC-3′
(forward) and 5′-CACAGGCTTTGGCTAGTCGT-3′ (reverse); 18S,
5′-ATTCGAACGTCTGCCCTATCA-3′ (forward) and 5′-GTCACCCGTGGTCACCATG-3′ (reverse).
Statistics. All data are expressed as mean ± SEM. All data were
normally distributed according to the Shapiro-Wilk normality test.
Data were analyzed by 2-way ANOVA. This analysis included the
main effects for tumor versus no tumor and treatment plus the
statistical interaction between tumor versus no tumor and treatment. When the statistical interaction was statistically significant
(P < 0.05) or suggestive of an important interaction, then unpaired
2-tailed t tests were used to compare the differences between the
treatment means for each animal strain, applying Bonferroni’s correction for multiple comparisons.
Study approval. All animal procedures were approved by the Institutional Animal Care and Use Committee of Emory University in
compliance with all applicable federal regulations governing the protection of animals in research.
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